Skip to main content
Top
Published in: Annals of Hematology 6/2020

01-06-2020 | Multiple Myeloma | Original Article

Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma

Authors: Xiao Ding, Wenyang Huang, Yi Peng, Hongqiong Fan, Yingqiao Zhu, Xuelian Liu, Yanping Yang, Qiang Guo, Lugui Qiu, Yun Dai, Dehui Zou, Fengyan Jin

Published in: Annals of Hematology | Issue 6/2020

Login to get access

Abstract

Autologous stem cell transplantation (ASCT) is the only curable therapy for multiple myeloma (MM), while its success primarily relies on mobilization to obtain sufficient hematopoietic stem/progenitor cells (HPC). Although the role of Pegfilgrastim (PEG), a novel PEGylated form of the recombinant G-CSF filgrastim (FIL), in mobilization has been demonstrated, it remains unclear whether this approach is cost-effective in MM treatment. Here, we performed a real-world analysis to evaluate the efficacy and cost of PEG for mobilization in a cohort of MM patients, of which 53% carried high-risk cytogenetic abnormalities. A total of 91 patients who received either a single dose of PEG (6 or 12 mg, n = 42) or multiple dosing of 10 μg/kg/day FIL (n = 49) after chemotherapy for HPC mobilization were included. The yield of MNCs and CD34+ cells per milliliter of blood collected via apheresis was significantly greater in the PEG group than that in the FIL group (P = 0.014 and P = 0.038). Mobilization with PEG yielded significantly higher median number of collected CD34+ cells than FIL (5.56 vs. 4.82 × 106/kg; P = 0.038). Moreover, the average time-to-recovery of leukocytes and platelets after transplantation was markedly shorter in the PEG group than that in the FIL group (leukocyte, 11.59 ± 1.98 vs 12.93 ± 2.83 days, P = 0.019; platelet, 12.86 ± 2.62 vs 14.80 ± 5.47, P = 0.085). However, the total cost of mobilization and apheresis using PEG or FIL was comparable (P = 0.486). Of note, mobilization with 12 mg PEG further shortened time-to-recovery of leukocytes (10.64 ± 0.51 vs. 12.04 ± 2.26 days, P = 0.05) and platelets (10.60 ± 2.89 vs. 13.33 ± 2.35 days, P = 0.031) compared with 6 mg PEG. Our results support a notion that PEG (especially 12 mg) combined with chemotherapy is a cost-effective and convenient regimen of mobilization, which might improve the outcome of ASCT in MM.
Literature
2.
go back to reference Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: intergroupe francais du myeloma. N Engl J Med 335:91–97CrossRefPubMed Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, Payen C, Bataille R (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: intergroupe francais du myeloma. N Engl J Med 335:91–97CrossRefPubMed
3.
go back to reference Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883CrossRefPubMed Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, Brown J, Drayson MT, Selby PJ, Medical Research Council Adult Leukaemia Working Party (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348:1875–1883CrossRefPubMed
4.
go back to reference Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP III (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transpl 13:183–196CrossRef Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP III (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transpl 13:183–196CrossRef
5.
go back to reference Cottler-Fox MH, Lapidot T, Petit I et al (2003) Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003:419–437CrossRef Cottler-Fox MH, Lapidot T, Petit I et al (2003) Stem cell mobilization. Hematology Am Soc Hematol Educ Program 2003:419–437CrossRef
6.
go back to reference Bensinger W, DiPersio JF, MacCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43:181–195CrossRefPubMed Bensinger W, DiPersio JF, MacCarty JM (2009) Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 43:181–195CrossRefPubMed
7.
go back to reference Mohti et al (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49:865–872CrossRef Mohti et al (2014) Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 49:865–872CrossRef
8.
go back to reference Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, di Nardo E, Perseghin P, Olivieri A (2018) Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplant 53:461–473. https://doi.org/10.1038/s41409-017-0051-y CrossRefPubMed Olivieri J, Attolico I, Nuccorini R, Pascale SP, Chiarucci M, Poiani M, Corradini P, Farina L, Gaidano G, Nassi L, Sica S, Piccirillo N, Pioltelli PE, Martino M, Moscato T, Pini M, Zallio F, Ciceri F, Marktel S, Mengarelli A, Musto P, Capria S, Merli F, Codeluppi K, Mele G, Lanza F, Specchia G, Pastore D, Milone G, Saraceni F, di Nardo E, Perseghin P, Olivieri A (2018) Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score. Bone Marrow Transplant 53:461–473. https://​doi.​org/​10.​1038/​s41409-017-0051-y CrossRefPubMed
9.
go back to reference Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 20:295–308CrossRefPubMed Giralt S, Costa L, Schriber J, DiPersio J, Maziarz R, McCarty J, Shaughnessy P, Snyder E, Bensinger W, Copelan E, Hosing C, Negrin R, Petersen FB, Rondelli D, Soiffer R, Leather H, Pazzalia A, Devine S (2014) Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 20:295–308CrossRefPubMed
10.
go back to reference Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724–1734CrossRefPubMed Molineux G, Kinstler O, Briddell B, Hartley C, McElroy P, Kerzic P, Sutherland W, Stoney G, Kern B, Fletcher FA, Cohen A, Korach E, Ulich T, McNiece I, Lockbaum P, Miller-Messana MA, Gardner S, Hunt T, Schwab G (1999) A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol 27:1724–1734CrossRefPubMed
12.
go back to reference Molineux G (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs 14:259–264CrossRefPubMed Molineux G (2003) Pegfilgrastim: using pegylation technology to improve neutropenia support in cancer patients. Anti-Cancer Drugs 14:259–264CrossRefPubMed
14.
go back to reference Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50:295–306CrossRefPubMed Yang BB, Kido A (2011) Pharmacokinetics and pharmacodynamics of pegfilgrastim. Clin Pharmacokinet 50:295–306CrossRefPubMed
15.
go back to reference Bakanay SM, Demirer T (2012) Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transplant 47:1154–1163CrossRefPubMed Bakanay SM, Demirer T (2012) Novel agents and approaches for stem cell mobilization in normal donors and patients. Bone Marrow Transplant 47:1154–1163CrossRefPubMed
16.
go back to reference Martino M, Laszlo D, Lanza F (2014) Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. Expert Opin Biol Ther 14:757–772CrossRefPubMed Martino M, Laszlo D, Lanza F (2014) Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. Expert Opin Biol Ther 14:757–772CrossRefPubMed
17.
go back to reference Biganzoli L, Untch M, Skacel T, Pico JL (2004) Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 31:27–34CrossRefPubMed Biganzoli L, Untch M, Skacel T, Pico JL (2004) Neulasta (pegfilgrastim): a once-per-cycle option for the management of chemotherapy-induced neutropenia. Semin Oncol 31:27–34CrossRefPubMed
18.
go back to reference Crawford J (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30:24–30CrossRefPubMed Crawford J (2003) Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia. Semin Oncol 30:24–30CrossRefPubMed
19.
go back to reference Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G (2005) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35:33–36CrossRefPubMed Steidl U, Fenk R, Bruns I, Neumann F, Kondakci M, Hoyer B, Gräf T, Rohr UP, Bork S, Kronenwett R, Haas R, Kobbe G (2005) Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 35:33–36CrossRefPubMed
20.
go back to reference Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion. 46:180–185CrossRefPubMed Bruns I, Steidl U, Kronenwett R, Fenk R, Graef T, Rohr UP, Neumann F, Fischer J, Scheid C, Hübel K, Haas R, Kobbe G (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion. 46:180–185CrossRefPubMed
21.
go back to reference Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo C, Baker N, Barker P, Skacel T, Schmitz N (2008) A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica. 93:405–412CrossRefPubMed Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo C, Baker N, Barker P, Skacel T, Schmitz N (2008) A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy. Haematologica. 93:405–412CrossRefPubMed
22.
go back to reference Putkonen M, Rauhala A, Pelliniemi TT, Remes K (2009) Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 88:673–680CrossRefPubMed Putkonen M, Rauhala A, Pelliniemi TT, Remes K (2009) Single-dose pegfilgrastim is comparable to daily filgrastim in mobilizing peripheral blood stem cells: a case-matched study in patients with lymphoproliferative malignancies. Ann Hematol 88:673–680CrossRefPubMed
23.
go back to reference Simona B, Cristina R, Luca N, Sara S, Aleksandra B, Paola B, Federica G, Pierluigi A, Laura O, Simona S, Jessica Q, Mara N, Giovanni M (2010) A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 43:321–326CrossRef Simona B, Cristina R, Luca N, Sara S, Aleksandra B, Paola B, Federica G, Pierluigi A, Laura O, Simona S, Jessica Q, Mara N, Giovanni M (2010) A single dose of pegfilgrastim versus daily filgrastim to evaluate the mobilization and the engraftment of autologous peripheral hematopoietic progenitors in malignant lymphoma patients candidate for high-dose chemotherapy. Transfus Apher Sci 43:321–326CrossRef
24.
go back to reference Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruuto T, Madrigal A, Johnsen HE, Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society (2013) Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 19:1670–1676CrossRefPubMed Lanza F, Campioni DC, Hellmann A, Milone G, Wahlin A, Walewski J, Spedini P, Fiamenghi C, Cuneo A, Knopińska W, Swierkowska-Czeneszew M, Petriz J, Fruehauf S, Farge D, Mohty M, Passweg J, Ruuto T, Madrigal A, Johnsen HE, Quality Assessment of Haematopoietic Stem Cell Grafting Committee of European Blood and Marrow Transplantation Society (2013) Individual quality assessment of autografting by probability estimation for clinical endpoints: a prospective validation study from the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 19:1670–1676CrossRefPubMed
25.
go back to reference Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473CrossRefPubMed Durie BG, Harousseau JL, Miguel JS et al (2006) International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473CrossRefPubMed
26.
go back to reference Kumar S, Paiva B2, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346CrossRef Kumar S, Paiva B2, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17:e328–e346CrossRef
28.
go back to reference Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P (2012) A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer 48:713–720CrossRefPubMed Sebban C, Lefranc A, Perrier L, Moreau P, Espinouse D, Schmidt A, Kammoun L, Ghesquieres H, Ferlay C, Bay JO, Lissandre S, Pérol D, Michallet M, Quittet P (2012) A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study). Eur J Cancer 48:713–720CrossRefPubMed
29.
go back to reference Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C (2013) Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy 11:129–138CrossRefPubMed Perrier L, Lefranc A, Pérol D, Quittet P, Schmidt-Tanguy A, Siani C, de Peretti C, Favier B, Biron P, Moreau P, Bay JO, Lissandre S, Jardin F, Espinouse D, Sebban C (2013) Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial. Appl Health Econ Health Policy 11:129–138CrossRefPubMed
30.
go back to reference Corso A, Caberlon S, Pagnucco G, Klersy C, Zappasodi P, Alessandrino EP, Vanelli L, Mangiacavalli S, Lazzarino M, Bernasconi C (2000) Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant 26:283–286CrossRefPubMed Corso A, Caberlon S, Pagnucco G, Klersy C, Zappasodi P, Alessandrino EP, Vanelli L, Mangiacavalli S, Lazzarino M, Bernasconi C (2000) Blood stem cell collections in multiple myeloma: definition of a scoring system. Bone Marrow Transplant 26:283–286CrossRefPubMed
31.
go back to reference Corso A, Mangiacavalli S, Nosari A et al (2005) Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 36:951–954CrossRefPubMed Corso A, Mangiacavalli S, Nosari A et al (2005) Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 36:951–954CrossRefPubMed
32.
go back to reference Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A (2008) DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion. 48:857–860CrossRefPubMed Zappasodi P, Nosari AM, Astori C, Ciapanna D, Bonfichi M, Varettoni M, Mangiacavalli S, Morra E, Lazzarino M, Corso A (2008) DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients. Transfusion. 48:857–860CrossRefPubMed
33.
go back to reference Herbert KE, Gambell P, Link EK, Mouminoglu A, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM (2013) Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant 48:351–356CrossRefPubMed Herbert KE, Gambell P, Link EK, Mouminoglu A, Wall DM, Harrison SJ, Ritchie DS, Seymour JF, Prince HM (2013) Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells. Bone Marrow Transplant 48:351–356CrossRefPubMed
34.
go back to reference Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T, Zeller LWJ, Moehler T, Ho AD, Goldschmidt H (2007) Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 39:743–750CrossRefPubMed Fruehauf S, Klaus J, Huesing J, Veldwijk MR, Buss EC, Topaly J, Seeger T, Zeller LWJ, Moehler T, Ho AD, Goldschmidt H (2007) Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 39:743–750CrossRefPubMed
35.
go back to reference Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD (2010) Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant 45:1522–1527CrossRefPubMed Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD (2010) Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant 45:1522–1527CrossRefPubMed
36.
go back to reference Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, McCullough J (1996) Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 36:601–610CrossRefPubMed Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, McCullough J (1996) Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+ cell counts and on the collection of peripheral blood stem cells. Transfusion. 36:601–610CrossRefPubMed
37.
go back to reference Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK (2012) Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 52:2375–2381CrossRefPubMed Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK (2012) Pegfilgrastim-versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis. Transfusion. 52:2375–2381CrossRefPubMed
38.
go back to reference Watts NL, Marques MB, Peavey DB, Innis-Shelton R, Saad A, di Stasi A, Salzman D, Lamb LS Jr, Costa LJ (2019) Mobilization of hematopoietic progenitor cells for autologous transplantation using Pegfilgrastim and plerixafor: efficacy and cost implications. Biol Blood Marrow Transplant 25:233–238CrossRefPubMed Watts NL, Marques MB, Peavey DB, Innis-Shelton R, Saad A, di Stasi A, Salzman D, Lamb LS Jr, Costa LJ (2019) Mobilization of hematopoietic progenitor cells for autologous transplantation using Pegfilgrastim and plerixafor: efficacy and cost implications. Biol Blood Marrow Transplant 25:233–238CrossRefPubMed
Metadata
Title
Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma
Authors
Xiao Ding
Wenyang Huang
Yi Peng
Hongqiong Fan
Yingqiao Zhu
Xuelian Liu
Yanping Yang
Qiang Guo
Lugui Qiu
Yun Dai
Dehui Zou
Fengyan Jin
Publication date
01-06-2020
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 6/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-019-03800-0

Other articles of this Issue 6/2020

Annals of Hematology 6/2020 Go to the issue